Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine

Journal of Human Hypertension

Volumn 10, Issue 3, 1996, Pages 185-192

  Agardh, C D ^a   Garcia Puig, J ^b   Charbonnel, B ^c   Angelkort, B ^d   Barnett, A H ^e  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Klinikzentrum Nord   (Germany)

^e BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Diabetes; Lisinopril; Nephropathy; Nifedipine

Indexed keywords

ALBUMIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; NIFEDIPINE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION; VERTIGO;

ADOLESCENT; ADULT; AGED; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; NIFEDIPINE;

EID: 0029866435     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Kannel WB, Wilson MD, Zhang T-J. The epidemiology of impaired glucose tolerance and hypertension. Am J Hypertens 1991; 121: 1268-1273.
2. Sowers JR, Khoury S. Diabetes and hypertension: a review. Primary Care 1991; 18: 509-524.
3. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as a predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988: ii: 530-532.
4. Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as a predictor of increased mortality in elderly people. Br Med J 1990; 300: 297-300.
5. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310: 356-360.
6. Jarrett RJ et al. Microalbuminuria predicts mortality in non-insulin dependent diabetes. Diabetic Med 1984; 1: 17-19.
7. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin dependent diabetes. A 10 year following study of 503 patients. Diabetic Med 1988; 5: 126-134.
8. Kikkawa R et al. Microalbuminuria associated with a rise in blood pressure in non-insulin-dependent diabetes. J Diabetic Complications 1989; 3: 99-102.
9. Jungmann E, Usadel KH. Renal long-term effects of calcium antagonist treatment in patients with diabetes mellitus. Clin Invest 1992; 70: 942-948.
10. Christensen CK, Mogensen CE. Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 1985; 7 (Suppl II): II109-II113.
11. Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 1990; 33: 470-476.
12. Marre M et al. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br Med J 1987; 294: 1448-1452.
13. Weber KT, Brilla CG, Cleland JGF. Cardioreparation and the concept of modulating cardiovascular structure and function. Blood Pressure 1993; 2: 6-21.
14. Mogensen CE, Christens CK. Blood pressure changes and renal function in incipient and overt diabetic nephropathy. Hypertension 1985; 7 (Suppl II); II64-1173.
15. Hasslacher C et al. Natural history of nephropathy in type I diabetes: relationship to metabolic control and blood pressure. Hypertension 1985; 7 (Suppl II): II74-II78.
16. Parving HH, Anderson AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; i: 1175-1178.
17. Mogensen CE. Long term antihypertensive treatment inhibits the progression of diabetic nephropathy. Br Med J 1982; 285: 685-688.
18. Noth RH. Diabetic nephropathy: haemodynamic basis and implications for disease management. Ann Intern Med 1989; 110: 795-813.
19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
20. Sano T et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994; 17: 420-442.
21. Holdaas H et al. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med 1991; 229: 163-170.
22. 2+ antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care 1991; 14: 911-914.
23. O'Donnell MJ et al. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study. J Human Hypertens 1993; 7: 333-339.
24. Mathiesen ER et al. Incipient nephropathy in type I (insulin-dependent) diabetes. Diabetologia 1984; 26: 406-410.
25. Romero R et al. Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diabetes Res Clin Pract 1992; 17: 191-198.
26. Parving HH, Rossing P. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 1994; 3: 292-300.
27. Kasiske BL et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138.
28. Jerums G et al. Comparison of early renal dysfunction in type I and type II diabetes: differing associations with blood pressure and glycaemic control. Diabetes Res Clin Pract 1988; 4: 133-141.
29. Ritz E, Hasslacher C, Mann J. Rational drug treatment of the hypertensive diabetic with nephropathy. J Diabet Complications 1988; 2: 171-174.
30. Jarrett RJ. Hypertension in diabetic patients and differences between insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1989; 13: 14-16.
31. Baba T, Murabyashi S, Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia 1989; 32: 40-44.
32. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 1991; 302: 210-216.
33. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. J Am Med Assoc 1994; 271: 275-279.
34. Ravid M et al. Long-term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581.
35. Lebovitz HE et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 1994; Suppl 45: S150-S155.
36. Schernthaner G, Schnack C, Hopmeier P. Effect of ramipril or atenolol on microalbuminuria and metabolic control parameters in type-2 diabetes mellitus. Diabetologia 1994; 37 (Suppl 1): A195 Abstract 752.
37. Gonera RK, Van Der Heel G, VanBoven WPL. Effects of lisinopril and metoprolol on microalbuminuria in hypertensive patients with non-insulin-dependent-diabetes-mellitus. Nephrology Dialysis Transplantation 1994; 9: 953 Abstract.
38. Friedman N, Anzalone D, Wilson A. Study Group. Efficacy of lisinopril (L) and nifedipine GITS (N) in hypertension associated with non-insulin dependent diabetes (NIDDM). Diabetes 1994; 43 (Suppl 1): 59A Abstract 186.
39. Chan JCN et al. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. Br Med J 1992; 305: 981-985.
40. Nielsen FS et al. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994; 43: 1108-1113.
41. Mogensen CE. Angiotensin converting enzyme inhibitors and diabetic nephropathy: their effects on proteinuria may be independent of their effects on blood pressure. Br Med J 1992; 304: 327-328.
42. Mai M et al. Early interstitial changes in hypertension-induced renal injury. Hypertension 1993; 22: 754-765.
43. Blumberg A. Fruherkennung und Behandlungs-moglichkeiten der diabetischen Nephropathie. (Early recognition of, and treatment possibilities in diabetic nephropathies). Schweiz Med Wochenschr 1986; 116: 275-281.
44. Diez J, Laviades C. Insulin-like growth factor I and collagen type III synthesis in patients with essential hypertension and left ventricular hypertrophy. J Human Hypertens 1994; 8 (Suppl 1): S21-S25.
45. Hasslacher C. Diabetische Nephropathie: 'Glomeruloreparation' mit Lisinopril (Diabetic nephropathy - 'glomeruloreparation' with lisinopril). Muench Med Woch 1991; 133 (Suppl 33): 5-7.
46. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
47. Yudkin JS. Factors influencing threshold and choice of treatment for hypertension in NIDDM. Cardiovascular factors. Diabetes Care 1991; 14 (Suppl 4): 27-32.